Doctor explaining FDA approval process to patient

Decoding FDA Approval: What It Means for Your ENT Treatments

Elliot Brynn monogram
Elliot Brynn in Health & Wellness October 2026 • 4 min read.

"A closer look at the clinical evidence behind new otolaryngology drugs and devices."


Navigating the world of medical treatments can be overwhelming, especially when it comes to understanding how new drugs and devices are approved. In otolaryngology (ENT), the Food and Drug Administration (FDA) plays a crucial role in ensuring that treatments are safe and effective before they reach the market. But what does FDA approval really mean, and how much evidence is actually required?

The FDA approves new prescription pharmaceuticals and high-risk devices based on premarket pivotal clinical studies designed to demonstrate their safety and efficacy. These studies vary in design and rigor, which can impact how confident doctors and patients are in the treatment's benefits. Understanding these variations is key to making informed decisions about your healthcare.

This article will break down the pivotal clinical evidence required for FDA approval of drugs and high-risk devices, and characterize variations in the strength of clinical evidence supporting FDA approval of novel otolaryngic therapeutics. By understanding the evidence, patients can have more informed conversations with their doctors about treatment options.

AI Search Multiple angles on this topic

Why FDA Approval Matters

FDA approval is an important checkpoint for treatments and devices used in otolaryngology. It indicates that a product has undergone the applicable regulatory review, although approval does not guarantee that it will work equally well for every patient. Patients should still discuss benefits, risks, alternatives, and follow-up with an ENT clinician.

Evaluating ENT Treatments

The standard approach is to consider the available clinical evidence alongside a patient's diagnosis, symptoms, medical history, and treatment goals. FDA approval can inform that discussion, but it does not replace individualized clinical judgment. Evidence may also have limitations, including differences between study populations and the circumstances of real-world care.

An Evolving Regulatory Landscape

ENT care has developed through successive advances in medical devices, medicines, diagnostics, and surgical techniques. FDA review has provided a regulatory framework for evaluating many of these innovations before they reach patients. The history of approval therefore reflects both scientific progress and changing methods for assessing safety and effectiveness.

The Evidence Behind the Approval: Drugs vs. Devices

Doctor explaining FDA approval process to patient

A recent study delved into the clinical evidence supporting FDA approvals between 2005 and 2014 for both drugs and devices used in otolaryngology. The study analyzed FDA documents to assess the strength of clinical evidence based on factors like:

The research examined 19 otolaryngic drugs (supported by 31 pivotal studies) and 14 devices (supported by 16 pivotal studies). Here’s what they found:

  • Enrollment: Drug studies had a median enrollment of 233 patients, while device studies enrolled a median of 122 patients.
  • Randomization and Blinding: Nearly all drug studies were randomized (97%) and blinded (81%). Device studies showed less consistency, with about 63% randomized and blinded.
  • Comparator: Most studies compared the new treatment against a placebo or an active treatment (94% for drugs, 50% for devices).
  • Primary Endpoint: Clinical outcomes and scales were the most common way to measure success, used in 74% of drug studies and 88% of device studies.
AI Search Multiple angles on this topic

Recent ENT Approvals

A state-of-the-art review examined new drugs and devices relevant to otolaryngology that were approved by the FDA in 2022, using publicly available FDA data and a preliminary screen for ENT relevance. A separate 2026 report states that the FDA approved Otarmeni on April 23 as the first gene therapy for a genetic form of hearing loss, following research involving OTOF gene therapy for DFNB9 patients. These examples show the range of innovation being evaluated, from broadly relevant devices and drugs to gene therapy for a rare inherited hearing-loss condition.

Approval Is Not a Guarantee

FDA approval should not be interpreted as a promise that a treatment will succeed for every patient or solve every clinical problem. Outcomes can vary according to the condition being treated, patient characteristics, treatment choices, and follow-up care. Patients and clinicians therefore need to weigh approved options against their limitations and alternatives.

Comparing Approval Reviews

The supplied sources describe similar review methods but do not agree on the approval year being evaluated. One source reports an analysis of drugs and devices approved in 2022, while another describes the objective as evaluating devices and drugs approved in 2021. Across the sources, reviewers screened FDA approvals for relevance to otolaryngology, and the AAO-HNS committee used subspecialty review to distinguish minor updates from new approvals.

The study revealed that the strength of clinical evidence supporting FDA approval varied considerably between drugs and devices. For instance, drug approvals typically relied on more randomized and blinded studies compared to devices. This difference reflects the distinct regulatory pathways and requirements for each type of product.

Making Informed Decisions: What to Discuss with Your Doctor

The key takeaway is that not all FDA-approved treatments are created equal. The evidence supporting approval can vary, so it’s crucial to have an open conversation with your otolaryngologist about the options available to you.

AI Search Multiple angles on this topic

Reading Approval Evidence Carefully

A review of FDA filings from 2019 examined medical devices and drugs with approvals or clearance relevant to otolaryngology. Its authors explicitly cautioned that the analysis did not represent the entirety of medical or technological innovation affecting the field. FDA approval reviews are therefore useful summaries of regulated developments, but they should not be treated as complete accounts of progress in ENT care.

What Comes Next

Future ENT advances may continue to include new devices, therapeutics, and biologic approaches. As these options develop, FDA review will remain one part of determining whether they can enter clinical use. The pace and direction of progress remain uncertain, so emerging treatments require continued evaluation rather than automatic acceptance.

The Wider Approval Context

FDA approval operates within a broader healthcare system that includes clinical expertise, access to care, costs, training, and long-term monitoring. A treatment may be authorized yet remain difficult for some patients to obtain or use. Understanding approval is therefore only one part of understanding how ENT care works in practice.

Evidence Beyond the Trial

The FDA defines real-world data as information about patient health status or healthcare delivery that is routinely collected from varied sources. An FDA effort identified 90 examples of real-world evidence use across the medical-device lifecycle and published them in 2021 as Examples of Real-World Evidence (RWE) Used in Medical Device Regulatory Decisions. Such evidence can help connect regulatory decisions with how devices perform in routine care.

Here are some questions to consider asking your doctor:

By understanding the level of evidence behind different treatments, you can work with your doctor to make the best choices for your specific needs and preferences. This proactive approach ensures you're an active participant in your healthcare journey.

How indication-level evidence was sized

  • 299For original indications, the median enrollment was 299 patients, compared with 197 for supplemental indications; the reported ranges were 198–613 and 64–442, respectively.[1]
  • 43%An active-controlled study supported 9 of 21 original indications (43%) and 7 of 27 supplemental indications (26%).[1]

What indication-level evidence can show

For dupilumab in chronic rhinosinusitis with nasal polyps, the review included a small number of recent clinical studies with relatively short follow-up. That makes its comparisons with endoscopic sinus surgery difficult to generalize confidently.[2]

Methods intended to increase round-window-membrane permeability are affected by variation between people, which limits how reliably those techniques can be applied clinically.[3]

How other evidence sources frame approval

A broader analysis of FDA approvals found larger treatment effects among treatments approved on nonrandomized trials than among those that underwent further randomized testing, but dramatic effects were uncommon among the nonrandomized-trial approvals.[4]

A review of postapproval evidence reported different counts of later clinical studies depending on whether initial approval relied on a single pivotal trial, surrogate markers, or both. This frames postapproval study activity as variable rather than a uniform follow-on process.[5]

For cochlear implants and other devices, FDA review considers product details, clinical-trial performance, and adverse effects in assessing safety and effectiveness.[6]

FDA guidance for drugs treating chronic rhinosinusitis with nasal polyps addresses trial population and design, effectiveness, statistical analysis, and safety, illustrating how development expectations can be specified for a particular condition.[7]

What further evidence would need to clarify

  • Would longer follow-up and a larger set of clinical studies change how confidently dupilumab’s effects can be generalized or compared with surgery?[2]
  • How could inner-ear delivery methods account for differences between people so that permeability changes are more reliable in clinical use?[3]

Sources

  1. Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014. (pubmed.ncbi.nlm.nih.gov)
  2. Effectiveness of Dupilumab Treatment to Treat Chronic Rhinosinusitis With Nasal Polyposis: A Systematic Review and Meta-Analysis (pmc.ncbi.nlm.nih.gov)
  3. Inner ear delivery: Challenges and opportunities (pmc.ncbi.nlm.nih.gov)
  4. US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials (pmc.ncbi.nlm.nih.gov)
  5. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review (pmc.ncbi.nlm.nih.gov)
  6. FDA-Approved Cochlear Implants | FDA (www.fda.gov)
  7. Chronic Rhinosinusitis with Nasal Polyps: Developing Drugs for Treatment | FDA (www.fda.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What does it mean when a drug or device receives FDA approval for use in otolaryngology?

The Food and Drug Administration (FDA) approval signifies that, based on pivotal clinical studies, a drug or high-risk device has been evaluated and deemed safe and effective for its intended use in otolaryngology. However, the strength of clinical evidence can vary.

2

What are some key characteristics of the pivotal clinical studies used to support FDA approval of otolaryngic drugs?

Pivotal clinical studies for otolaryngic drugs often involve larger patient enrollments compared to device studies. Drug studies typically employ randomization and blinding more frequently, and often compare the new treatment against a placebo or an active treatment. The primary endpoint is frequently measured through clinical outcomes and scales.

3

What specific questions should I ask my otolaryngologist to better understand the clinical evidence supporting an FDA-approved treatment?

When discussing treatment options with your otolaryngologist, inquire about the specifics of the pivotal clinical studies that supported the FDA approval. Discuss factors such as the study design, the number of patients enrolled, whether the study was randomized and blinded, what comparators were used, and what the primary endpoint was. Understanding these details will help you assess the strength of the clinical evidence and make an informed decision.

4

Why might there be differences in the clinical evidence required for FDA approval of drugs compared to devices in otolaryngology?

The variance in clinical evidence between drugs and devices stems from distinct regulatory pathways and requirements. Drug approvals generally require more rigorous clinical trials with stringent controls, while device approvals may involve different evaluation criteria, especially if the device represents a significant innovation or addresses an unmet clinical need. This does not necessarily mean devices are less safe or effective, but the nature of evidence supporting their approval can differ.

5

Does FDA approval guarantee long-term effectiveness and safety, or are there other considerations beyond the initial pivotal clinical studies?

While the FDA approval process focuses on safety and efficacy based on pivotal clinical studies, it doesn't replace the need for ongoing post-market surveillance. Long-term effectiveness, rare side effects, and the performance of devices in diverse patient populations are often monitored after approval. Post-market data adds to the overall understanding of a treatment's benefits and risks over time, complementing the pre-approval pivotal clinical evidence.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.